Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy

NCT01085058 is registered in ClinicalTrials.gov with WiSP Wissenschaftlicher Service Pharma GmbH as lead sponsor.

NCT NCT01085058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01085058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy
Lead sponsor
WiSP Wissenschaftlicher Service Pharma GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2003
Completion date
December 31, 2004
Enrollment
169 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's disease, multiple myelomas, non-hodgkin lymphomas